Table 3.
Adverse reactions (n = 43)
| Grade | ||||||
|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | Total | ||
| n | n | n | n | n | (%) | |
| Hematological toxicities | ||||||
| Neutropenia | 7 | 8 | 1 | 0 | 19 | (44.2%) |
| Leukopenia | 5 | 21 | 2 | 0 | 28 | (65.1%) |
| Thrombocytopenia | 13 | 0 | 0 | 0 | 13 | (30.2%) |
| Anemia (Hb) | 11 | 3 | 0 | 0 | 14 | (32.6%) |
| AST | 12 | 0 | 0 | 0 | 12 | (27.9%) |
| ALT | 11 | 0 | 0 | 0 | 11 | (25.6%) |
| Total bilirubin | 7 | 1 | 0 | 0 | 8 | (18.6%) |
| Creatinine | 2 | 0 | 0 | 0 | 2 | (4.6%) |
| Non-hematological toxicities | ||||||
| Anorexia | 24 | 4 | 0 | 0 | 28 | (65.1%) |
| General Fatigue | 29 | 2 | 0 | 0 | 31 | (72.1%) |
| Diarrhea | 13 | 0 | 2 | 0 | 15 | (34.9%) |
| Nausea | 12 | 4 | 0 | 0 | 16 | (37.2%) |
| Stomatitis | 15 | 1 | 0 | 0 | 16 | (37.2%) |
| Pigmentation changes | 17 | 3 | 0 | 0 | 20 | (46.5%) |
| Rash | 3 | 1 | 0 | 0 | 4 | (9.3%) |